In terms of earnings growth today, Pfizer (PFE)
is just a middling Big Pharma pick. On a longer-term basis, though, it
looks as if the Street is still undervaluing the company's ability to
continue to earn strong economic profits and return capital to
shareholders. While the near-term news flow has not been great and the
company will be hard-pressed to post major earnings growth without a
large transaction, there is still value here for the patient
shareholder.
Click here for more:
Pfizer's Trade-Off Between Value And Momentum
No comments:
Post a Comment